A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Lars Køber, M.D., Christian Torp-Pedersen, M.D., Ph.D., Jan E. Carlsen, M.D., Henning Bagger, M.D., Ph.D., Per Eliasen, M.D., Ph.D., Kjeld Lyngborg, M.D., Ph.D., Jørgen Videbæk, M.D., Ph.D., David S. Cole, Ph.D., Laurent Auclert, M.D., Nancy C. Pauly, M.D., Etienne Aliot, M.D., Stig Persson, M.D., Ph.D., A. John Camm, M.D., for The Trandolapril Cardiac Evaluation (TRACE) study group
Background Treatment with angiotensin-converting–enzyme(ACE) inhibitors reduces mortality among survivors of acutemyocardial infarction, but whether to use ACE inhibitors inall patients or only in selected patients is uncertain.
Methods We screened 6676 consecutive patients with 7001 myocardialinfarctions confirmed by enzyme studies. A total of 2606 patientshad echocardiographic evidence of left ventricular systolicdysfunction (ejection fraction, <35 percent). On days 3 to7 after infarction, 1749 patients were randomly assigned toreceive oral trandolapril (876 patients) or placebo (873 patients).The duration of follow-up was 24 to 50 months.
Results During the study period, 304 patients (34.7 percent)in the trandolapril group died, as compared with 369 (42.3 percent)in the placebo group (P = 0.001). The relative risk of deathin the trandolapril group, as compared with the placebo group,was 0.78 (95 percent confidence interval, 0.67 to 0.91). Trandolaprilalso reduced the risk of death from cardiovascular causes (relativerisk, 0.75; 95 percent confidence interval, 0.63 to 0.89; P= 0.001) and sudden death (relative risk, 0.76; 95 percent confidenceinterval, 0.59 to 0.98; P = 0.03). Progression to severe heartfailure was less frequent in the trandolapril group (relativerisk, 0.71; 95 percent confidence interval, 0.56 to 0.89; P= 0.003). In contrast, the risk of recurrent myocardial infarction(fatal or nonfatal) was not significantly reduced (relativerisk, 0.86; 95 percent confidence interval, 0.66 to 1.13; P= 0.29).
Conclusions Long-term treatment with trandolapril in patientswith reduced left ventricular function soon after myocardialinfarction significantly reduced the risk of overall mortality,mortality from cardiovascular causes, sudden death, and thedevelopment of severe heart failure. That mortality was reducedin a randomized study enrolling 25 percent of consecutive patientsscreened should encourage the selective use of ACE inhibitionafter myocardial infarction.
Source Information
From the Department of Cardiology, Gentofte University Hospital (L.K., C.T.-P.), and the Trace Study Office (J.E.C.), Copenhagen, Denmark; Esbjerg Hospital, Esbjerg, Denmark (H.B.); Slagelse Hospital, Slagelse, Denmark (P.E.); Frederiksberg Hospital, Frederiksberg, Denmark (K.L.); Bispebjerg Hospital, Copenhagen, Denmark (J.V.); the Knebworth Consultancy, Knebworth, United Kingdom (D.S.C.); Roussel–Uclaf, Romainville, France (L.A., N.C.P.); Hôpital Central, Nancy, France (E.A.); University Hospital of Malmö, Malmö, Sweden (S.P.); and St. George's Hospital Medical School, London (A.J.C.).
Address reprint requests to the TRACE Study Office, Svanemøllevej 2, DK-2100 Copenhagen, Denmark.
Ferrari, R.
(2008). Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection. Eur Heart J Suppl
10: G13-G20
[Abstract][Full Text]
Schindler, C.
(2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Therapeutic Advances in Cardiovascular Disease
2: 233-248
[Abstract]
Prisant, L. M., Thomas, K. L., Lewis, E. F., Huang, Z., Francis, G. S., Weaver, W. D., Pfeffer, M. A., McMurray, J. J.V., Califf, R. M., Velazquez, E. J.
(2008). Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. J Am Coll Cardiol
51: 1865-1871
[Abstract][Full Text]
Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., Hong, Y.
(2008). Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation
117: 2544-2565
[Abstract][Full Text]
Pilote, L. MD PhD, Abrahamowicz, M. PhD, Eisenberg, M. MD MPH, Humphries, K. DSc, Behlouli, H. MSc PhD, Tu, J. V. MD PhD
(2008). Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ
178: 1303-1311
[Abstract][Full Text]
Hernandez, A. F. MD MHS, Harrington, R. A. MD
(2008). Comparative effectiveness of angiotensin-converting-enzyme inhibitors: Is an ACE always an ace?. CMAJ
178: 1316-1319
[Full Text]
Verjans, J. W.H., Lovhaug, D., Narula, N., Petrov, A. D., Indrevoll, B., Bjurgert, E., Krasieva, T. B., Petersen, L. B., Kindberg, G. M., Solbakken, M., Cuthbertson, A., Vannan, M. A., Reutelingsperger, C. P.M., Tromberg, B. J., Hofstra, L., Narula, J.
(2008). Noninvasive Imaging of Angiotensin Receptors After Myocardial Infarction. J Am Coll Cardiol Img
1: 354-362
[Abstract][Full Text]
Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L., Galloway, J. M., Henderson, J. A., Howard, Wm. J., Lee, E. T., Mete, M., Poolaw, B., Ratner, R. E., Russell, M., Silverman, A., Stylianou, M., Umans, J. G., Wang, W., Weir, M. R., Weissman, N. J., Wilson, C., Yeh, F., Zhu, J.
(2008). Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA
299: 1678-1689
[Abstract][Full Text]
Albert, N. M., Lewis, C.
(2008). Recognizing and Managing Asymptomatic Left Ventricular Dysfunction: After Myocardial Infarction. Crit Care Nurse
28: 20-37
[Full Text]
Abdulla, J., Kober, L., Abildstrom, S. Z., Christensen, E., James, W. P. T., Torp-Pedersen, C.
(2008). Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. Eur Heart J
29: 594-601
[Abstract][Full Text]
Borer, J. S.
(2007). Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases. Eur Heart J Suppl
9: E2-E9
[Abstract][Full Text]
Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S.
(2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension
50: e28-e55
[Full Text]
Yap, Y. G., Duong, T., Bland, J M., Malik, M., Torp-Pedersen, C., Kober, L., Gallagher, M. M, Camm, A J.
(2007). Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction. Heart
93: 832-836
[Abstract][Full Text]
Kasi, V. S., Xiao, H. D., Shang, L. L., Iravanian, S., Langberg, J., Witham, E. A., Jiao, Z., Gallego, C. J., Bernstein, K. E., Dudley, S. C. Jr.
(2007). Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation. Am. J. Physiol. Heart Circ. Physiol.
293: H182-H192
[Abstract][Full Text]
Frohlich, E. D.
(2007). The Salt Conundrum: A Hypothesis. Hypertension
50: 161-166
[Full Text]
Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S.
(2007). Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation
115: 2761-2788
[Full Text]
Ceconi, C., Fox, K. M., Remme, W. J., Simoons, M. L., Bertrand, M., Parrinello, G., Kluft, C., Blann, A., Cokkinos, D., Ferrari, R.
(2007). ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res
73: 237-246
[Abstract][Full Text]
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W.
(2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation
114: 2871-2891
[Full Text]
Edwards, N.C., Steeds, R.P., Ferro, C.J., Townend, J.N.
(2006). The treatment of coronary artery disease in patients with chronic kidney disease. QJM
99: 723-736
[Abstract][Full Text]
Pfeffer, M. A., Frohlich, E. D.
(2006). Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am. J. Physiol. Heart Circ. Physiol.
291: H2021-H2025
[Abstract][Full Text]
Gheorghiade, M., Sopko, G., De Luca, L., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D. L., Rouleau, J. L., Bonow, R. O.
(2006). Navigating the Crossroads of Coronary Artery Disease and Heart Failure. Circulation
114: 1202-1213
[Full Text]
Fox, K., Ferrari, R., Yusuf, S., Borer, J. S.
(2006). Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. Eur Heart J
27: 2154-2157
[Abstract][Full Text]
Dolezal, T.
(2006). Review: Imidapril in Heart Failure. Journal of Renin-Angiotensin-Aldosterone System
7: 146-154
[Abstract]
Solomon, S. D., Rice, M. M., A. Jablonski, K., Jose, P., Domanski, M., Sabatine, M., Gersh, B. J., Rouleau, J., Pfeffer, M. A., Braunwald, E., for the Prevention of Events with ACE inhibition (,
(2006). Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial. Circulation
114: 26-31
[Abstract][Full Text]
Goldberg, L. R., Jessup, M.
(2006). Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction. Circulation
113: 2851-2860
[Full Text]
Lechat, P.
(2006). The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Eur Heart J Suppl
8: C5-C12
[Abstract][Full Text]
Funck-Brentano, C.
(2006). Beta-blockade in CHF: from contraindication to indication. Eur Heart J Suppl
8: C19-C27
[Abstract][Full Text]
Ponikowski, P.
(2006). Rationale and design of CIBIS III. Eur Heart J Suppl
8: C35-C42
[Abstract][Full Text]
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Gadsboll, N., Buch, P., Friberg, J., Rasmussen, S., Kober, L., Stender, S., Madsen, M., Torp-Pedersen, C.
(2006). Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J
27: 1153-1158
[Abstract][Full Text]
Mehta, P A, Cowie, M R
(2006). Gender and heart failure: a population perspective. Heart
92: iii14-iii18
[Full Text]
Al-Mallah, M. H., Tleyjeh, I. M., Abdel-Latif, A. A., Weaver, W. D.
(2006). Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol
47: 1576-1583
[Abstract][Full Text]
Volpe, M., Tocci, G., Pagannone, E.
(2006). Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System.. J. Am. Soc. Nephrol.
17: S36-S43
[Abstract][Full Text]
McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., White, H., Howlett, J., Swedberg, K., Maggioni, A., Kober, L., Van de Werf, F., Califf, R., Pfeffer, M.
(2006). The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction: An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol
47: 726-733
[Abstract][Full Text]
Aronow, W. S.
(2005). Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. J. Gerontol. A Biol. Sci. Med. Sci.
60: 1597-1605
[Abstract][Full Text]
Prepared by: British Cardiac Society, British Hype,
(2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart
91: v1-v52
[Full Text]
Reiffel, J. A.
(2005). Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. J CARDIOVASC PHARMACOL THER
10: S45-S58
[Abstract]
Yap, Y. G., Duong, T., Bland, M., Malik, M., Torp-Pedersen, C., Kober, L., Connolly, S. J., Marchant, B., Camm, J.
(2005). Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J
26: 1385-1393
[Abstract][Full Text]
Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., Connolly, S. J.
(2005). Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis. J Am Coll Cardiol
45: 1832-1839
[Abstract][Full Text]
Granger, C. B
(2005). Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. Evid. Based Med.
10: 78-78
[Full Text]
Authors/Task Force Members, , Swedberg, K., Writing Committee:, , Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Other Contributors, , Gavazzi, A., Haverich, A., Hoes, A., Jaarsma, T., Korewicki, J., Levy, S., Linde, C., Lopez-Sendon, J.-L., Nieminen, M. S., Pierard, L., Remme, W. J.
(2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J
26: 1115-1140
[Full Text]
Cleland, J G F, Torabi, A, Khan, N K
(2005). Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart
91: ii7-ii13
[Abstract][Full Text]
Weir, R, McMurray, J J V
(2005). Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart
91: ii17-ii20
[Abstract][Full Text]
McDonagh, T A
(2005). Lessons from the management of chronic heart failure. Heart
91: ii24-ii27
[Abstract][Full Text]
Yusuf, S., Pogue, J., Myers, M. G., McCullough, C., Pfeffer, M. A., Domanski, M. J., Braunwald, E.
(2005). ACE Inhibition in Stable Coronary Artery Disease. NEJM
352: 937-939
[Full Text]
Boyle, A. J, Schuster, M., Witkowski, P., Guosheng Xiang, , Seki, T., Way, K., Itescu, S.
(2005). Additive effects of endothelial progenitor cells combined with ACE inhibition and {beta}-blockade on left ventricular function following acute myocardial infarction. Journal of Renin-Angiotensin-Aldosterone System
6: 33-37
[Abstract]
Anavekar, N. S, Solomon, S. D
(2005). Angiotensin II receptor blockade and ventricular remodelling. Journal of Renin-Angiotensin-Aldosterone System
6: 43-48
[Abstract]
Lazar, H. L.
(2005). Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient. Ann. Thorac. Surg.
79: 1081-1089
[Abstract][Full Text]
Takahashi, M., Tanonaka, K., Yoshida, H., Oikawa, R., Koshimizu, M., Daicho, T., Toyo-oka, T., Takeo, S.
(2005). Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. Cardiovasc Res
65: 356-365
[Abstract][Full Text]
Yan, A. T., Yan, R. T., Liu, P. P.
(2005). Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. ANN INTERN MED
142: 132-145
[Abstract][Full Text]
Buch, P., Rasmussen, S., Abildstrom, S. Z., Kober, L., Carlsen, J., Torp-Pedersen, C., on behalf of the TRACE investigators,
(2005). The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J
26: 145-152
[Abstract][Full Text]
Plummer, C. J., Irving, R. J., McComb, J. M.
(2005). The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. Europace
7: 266-272
[Abstract][Full Text]
de Kam, P. J, Voors, A. A, Fici, F., van Veldhuisen, D. J, van Gilst, W. H
(2004). Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. Journal of Renin-Angiotensin-Aldosterone System
5: 161-168
[Abstract]
The PEACE Trial Investigators,
(2004). Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. NEJM
351: 2058-2068
[Abstract][Full Text]
Koren, M. J., Hunninghake, D. B., the ALLIANCE Investigators,
(2004). Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study. J Am Coll Cardiol
44: 1772-1779
[Abstract][Full Text]
Leier, C. V.
(2004). Dismantling mandates in the treatment of heart failure. J Am Coll Cardiol
44: 1831-1833
[Full Text]
Kragelund, C., Snorgaard, O., Kober, L., Bengtsson, B., Ottesen, M., Hojberg, S., Olesen, C., Kjaergaard, J.-J., Carlsen, J., Torp-Petersen, C., on behalf of the TRACE Study Group,
(2004). Hyperinsulinaemia is associated with increased long-term mortality following acute myocardial infarction in non-diabetic patients. Eur Heart J
25: 1891-1897
[Abstract][Full Text]
Velazquez, E. J., Francis, G. S., Armstrong, P. W., Aylward, P. E., Diaz, R., O'Connor, C. M., White, H. D., Henis, M., Rittenhouse, L. M., Kilaru, R., Gilst, W. v., Ertl, G., Maggioni, A. P., Spac, J., Weaver, W. D., Rouleau, J.-L., McMurray, J. J.V., Pfeffer, M. A., Califf, R. M.
(2004). An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J
25: 1911-1919
[Abstract][Full Text]
Aronow, W. S.
(2004). Management of the Elderly Person After Myocardial Infarction. J. Gerontol. A Biol. Sci. Med. Sci.
59: 1173-1185
[Abstract][Full Text]
Tomaselli, G. F., Zipes, D. P.
(2004). What Causes Sudden Death in Heart Failure?. Circ. Res.
95: 754-763
[Abstract][Full Text]
Teo, K. K., Mitchell, L. B., Pogue, J., Bosch, J., Dagenais, G., Yusuf, S., on behalf of the HOPE Investigators,
(2004). Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. Circulation
110: 1413-1417
[Abstract][Full Text]
Suzuki, S., Yoshimura, M., Nakayama, M., Mizuno, Y., Harada, E., Ito, T., Nakamura, S., Abe, K., Yamamuro, M., Sakamoto, T., Saito, Y., Nakao, K., Yasue, H., Ogawa, H.
(2004). Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction: A Long-Term Follow-Up Analysis. Circulation
110: 1387-1391
[Abstract][Full Text]
Rosenkranz, S.
(2004). TGF-{beta}1 and angiotensin networking in cardiac remodeling. Cardiovasc Res
63: 423-432
[Abstract][Full Text]
Gluckman, T. J., Baranowski, B., Ashen, M. D., Henrikson, C. A., McAllister, M., Braunstein, J. B., Blumenthal, R. S.
(2004). A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction. Arch Intern Med
164: 1490-1500
[Abstract][Full Text]
Pilote, L., Abrahamowicz, M., Rodrigues, E., Eisenberg, M. J., Rahme, E.
(2004). Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect?. ANN INTERN MED
141: 102-112
[Abstract][Full Text]
Tian, X.-L., Pinto, Y. M., Costerousse, O., Franz, W. M., Lippoldt, A., Hoffmann, S., Unger, T., Paul, M.
(2004). Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet
13: 1441-1450
[Abstract][Full Text]
Franco, V., Oparil, S., Carretero, O. A.
(2004). Hypertensive Therapy: Part II. Circulation
109: 3081-3088
[Full Text]
Field, K. M., Pepin, J. L., Mehta, M. D.
(2004). Knowing When to Play the Ace: The Use and Under Use of Ace Inhibitors in Primary Practice. Journal of Pharmacy Practice
17: 197-210
[Abstract]
Prystowsky, E. N.
(2004). Primary Prevention of Sudden Cardiac Death: The Time of Your Life. Circulation
109: 1073-1075
[Full Text]
Westendorp, B., Schoemaker, R. G, Buikema, H., de Zeeuw, D., van Veldhuisen, D. J, van Gilst, W. H
(2004). Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. Journal of Renin-Angiotensin-Aldosterone System
5: 27-32
[Abstract]
Drexler, H., Wollert, K. C
(2004). Reassessing guidelines for heart failure. Journal of Renin-Angiotensin-Aldosterone System
5: S28-S33
[Abstract]
Lopez-Jimenez, F., Goraya, T. Y., Hellermann, J. P., Jacobsen, S. J., Reeder, G. S., Weston, S. A., Roger, V. L.
(2004). Measurement of Ejection Fraction After Myocardial Infarction in the Population. Chest
125: 397-403
[Abstract][Full Text]
Tsikouris, J. P., Suarez, J. A., Meyerrose, G. E., Ziska, M., Fike, D., Smith, J.
(2004). Questioning a Class Effect: Does ACE Inhibitor Tissue Penetration Influence the Degree of Fibrinolytic Balance Alteration following an Acute Myocardial Infarction?. J Clin Pharmacol
44: 150-157
[Abstract][Full Text]
Laverman, G. D., Remuzzi, G., Ruggenenti, P.
(2004). ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection?. J. Am. Soc. Nephrol.
15: S64-70
[Abstract][Full Text]
Pepine, C. J., Rouleau, J.-L., Annis, K., Ducharme, A., Ma, P., Lenis, J., Davies, R., Thadani, U., Chaitman, B., Haber, H. E., Freedman, S. B., Pressler, M. L., Pitt, B., QUASAR Study Group,
(2003). Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial. J Am Coll Cardiol
42: 2049-2059
[Abstract][Full Text]
Abdulla, J., Burchardt, H., Abildstrom, S. Z., Kober, L., Torp-Pedersen, C., On behalf of TRACE study group,
(2003). The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. Eur Heart J
24: 2116-2122
[Abstract][Full Text]
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr, Roccella, E. J., the National High Blood Pressure Education Program,
(2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension
42: 1206-1252
[Abstract][Full Text]
Pfeffer, M. A., McMurray, J. J.V., Velazquez, E. J., Rouleau, J.-L., Kober, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J. D., Henis, M., Edwards, S., Zelenkofske, S., Sellers, M. A., Califf, R. M., the Valsartan in Acute Myocardial Infarction Trial,
(2003). Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. NEJM
349: 1893-1906
[Abstract][Full Text]
McKenzie, D B, Cowley, A J
(2003). Drug therapy in chronic heart failure. Postgrad. Med. J.
79: 634-642
[Abstract][Full Text]
Coletta, C, Sestili, A, Seccareccia, F, Rambaldi, R, Ricci, R, Galati, A, Bigi, R, Aspromonte, N, Renzi, M, Ceci, V
(2003). Influence of contractile reserve and inducible ischaemia on left ventricular remodelling after acute myocardial infarction. Heart
89: 1138-1143
[Abstract][Full Text]
van der Elst, M. E, Buurma, H., Bouvy, M. L, de Boer, A.
(2003). Drug Therapy for Prevention of Recurrent Myocardial Infarction. The Annals of Pharmacotherapy
37: 1465-1477
[Abstract][Full Text]
Jennings, G.
(2003). New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?. Eur Heart J Suppl
5: F3-F11
[Abstract]
Bertrand, M.E., Bassand, J.-P.
(2003). New evidence for angiotensin-converting enzyme inhibition in stroke, cardiac and renal patients: the cardiological approach. Eur Heart J Suppl
5: E1-E3
Wang, T. J., Levy, D., Benjamin, E. J., Vasan, R. S.
(2003). The Epidemiology of "Asymptomatic" Left Ventricular Systolic Dysfunction: Implications for Screening. ANN INTERN MED
138: 907-916
[Abstract][Full Text]
Shlipak, M. G.
(2003). Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency. ANN INTERN MED
138: 917-924
[Abstract][Full Text]
Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2003). Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure. JNM
44: 884-890
[Abstract][Full Text]
Borghi, C., Bacchelli, S., Esposti, D. D., Ambrosioni, E.
(2003). Effects of the Early ACE Inhibition in Diabetic Nonthrombolyzed Patients With Anterior Acute Myocardial Infarction. Diabetes Care
26: 1862-1868
[Abstract][Full Text]
Jacoby, D. S., Rader, D. J.
(2003). Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment. Arch Intern Med
163: 1155-1164
[Abstract][Full Text]
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr, Roccella, E. J.
(2003). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA
289: 2560-2571
[Abstract][Full Text]
Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, Col. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., Heidenreich, P. A., Knabel, T., Konstam, M. A., Steimle, A., Warner Stevenson, L.
(2003). Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol
41: 1529-1538
[Abstract][Full Text]
Arnold, J. M. O., Yusuf, S., Young, J., Mathew, J., Johnstone, D., Avezum, A., Lonn, E., Pogue, J., Bosch, J., on behalf of the HOPE Investigators,
(2003). Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation
107: 1284-1290
[Abstract][Full Text]
Douglas, J. G., Bakris, G. L., Epstein, M., Ferdinand, K. C., Ferrario, C., Flack, J. M., Jamerson, K. A., Jones, W. E., Haywood, J., Maxey, R., Ofili, E. O., Saunders, E., Schiffrin, E. L., Sica, D. A., Sowers, J. R., Vidt, D. G., the Hypertension in African Americans Working Grou,
(2003). Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med
163: 525-541
[Full Text]
Dubey, K, Balani, D K, Pillai, K K
(2003). Potential adverse interaction between aspirin and Lisinopril in hypertensive rats. Hum Exp Toxicol
22: 143-147
[Abstract]
Muntoni, F.
(2003). Cardiac Complications of Childhood Myopathies. J Child Neurol
18: 191-202
[Abstract]
Hamon, M, Fradin, S, Denizet, A, Filippi-Codaccioni, E, Grollier, G, Morello, R
(2003). Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Heart
89: 321-325
[Abstract][Full Text]
The Task Force on the Management of Acute Myocardi, , Van de Werf, F., Ardissino, D., Betriu, A., Cokkinos, D. V., Falk, E., Fox, K. A.A., Julian, D., Lengyel, M., Neumann, F.-J., Ruzyllo, W., Thygesen, C., Underwood, S. R., Vahanian, A., Verheugt, F. W.A., Wijns, W.
(2003). Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J
24: 28-66
[Full Text]
Previous
